Companies House 15297064 2025-11-30 2025-11-30 2024-12-01 false iso4217:GBP xbrli:pure 15297064 2023-11-20 2024-11-30 15297064 2025-11-30 15297064 2024-12-01 2025-11-30 15297064 2024-11-30 15297064 curr:PoundSterling 2024-12-01 2025-11-30 15297064 uk-bus:CompanyLimitedByGuarantee 2024-12-01 2025-11-30 15297064 uk-bus:FRS102 2024-12-01 2025-11-30 15297064 uk-bus:AuditExempt-NoAccountantsReport 2024-12-01 2025-11-30 15297064 uk-bus:FullAccounts 2024-12-01 2025-11-30 15297064 uk-bus:RegisteredOffice 2024-12-01 2025-11-30 15297064 uk-bus:Director1 2024-12-01 2025-11-30 15297064 uk-bus:Director2 2024-12-01 2025-11-30 15297064 uk-bus:Director3 2024-12-01 2025-11-30 15297064 uk-bus:Director4 2024-12-01 2025-11-30 15297064 uk-bus:Director5 2024-12-01 2025-11-30 15297064 uk-bus:Director6 2024-12-01 2025-11-30 15297064 uk-bus:Director7 2024-12-01 2025-11-30 15297064 uk-bus:Director8 2024-12-01 2025-11-30 15297064 uk-bus:Director9 2024-12-01 2025-11-30 15297064 uk-bus:Director10 2024-12-01 2025-11-30 15297064 uk-bus:Director11 2024-12-01 2025-11-30 15297064 uk-bus:Director12 2024-12-01 2025-11-30 15297064 uk-bus:Director13 2024-12-01 2025-11-30 15297064 uk-bus:Director14 2024-12-01 2025-11-30 15297064 uk-bus:Director15 2024-12-01 2025-11-30 15297064 uk-bus:Director16 2024-12-01 2025-11-30 15297064 uk-bus:Director17 2024-12-01 2025-11-30 15297064 uk-bus:Director18 2024-12-01 2025-11-30 15297064 uk-bus:Director19 2024-12-01 2025-11-30 15297064 uk-bus:Director20 2024-12-01 2025-11-30 15297064 uk-bus:Director21 2024-12-01 2025-11-30 15297064 uk-bus:CompanySecretary1 2024-12-01 2025-11-30 15297064 core:AfterOneYear 2025-11-30 15297064 core:AfterOneYear 2024-11-30 15297064 core:WithinOneYear 2025-11-30 15297064 core:WithinOneYear 2024-11-30 15297064 core:WithinOneYear 2024-12-01 2025-11-30 15297064 core:AfterOneYear 2025-11-30 15297064 core:AfterOneYear 2024-11-30 15297064 core:AfterOneYear 2024-12-01 2025-11-30 15297064 core:ShareCapital 2025-11-30 15297064 core:ShareCapital 2024-11-30 15297064 core:SharePremium 2025-11-30 15297064 core:SharePremium 2024-11-30 15297064 core:OtherReservesSubtotal 2025-11-30 15297064 core:OtherReservesSubtotal 2024-11-30 15297064 core:RevaluationReserve 2025-11-30 15297064 core:RevaluationReserve 2024-11-30 15297064 core:RetainedEarningsAccumulatedLosses 2025-11-30 15297064 core:RetainedEarningsAccumulatedLosses 2024-11-30 15297064 1 2024-12-01 2025-11-30 15297064 2 2024-12-01 2025-11-30 15297064 3 2024-12-01 2025-11-30 15297064 core:LandBuildings 2024-12-01 2025-11-30 15297064 core:LandBuildings 2025-11-30 15297064 core:LandBuildings 2023-11-20 2024-11-30 15297064 core:LandBuildings 2024-11-30 15297064 core:PlantMachinery 2024-12-01 2025-11-30 15297064 core:PlantMachinery 2025-11-30 15297064 core:PlantMachinery 2023-11-20 2024-11-30 15297064 core:PlantMachinery 2024-11-30 15297064 core:FurnitureFittingsToolsEquipment 2024-12-01 2025-11-30 15297064 core:FurnitureFittingsToolsEquipment 2025-11-30 15297064 core:FurnitureFittingsToolsEquipment 2023-11-20 2024-11-30 15297064 core:FurnitureFittingsToolsEquipment 2024-11-30 15297064 core:OfficeEquipment 2024-12-01 2025-11-30 15297064 core:OfficeEquipment 2025-11-30 15297064 core:OfficeEquipment 2023-11-20 2024-11-30 15297064 core:OfficeEquipment 2024-11-30 15297064 core:Vehicles 2024-12-01 2025-11-30 15297064 core:Vehicles 2025-11-30 15297064 core:Vehicles 2023-11-20 2024-11-30 15297064 core:Vehicles 2024-11-30 15297064 core:NetGoodwill 2024-12-01 2025-11-30 15297064 core:NetGoodwill 2025-11-30 15297064 core:NetGoodwill 2023-11-20 2024-11-30 15297064 core:NetGoodwill 2024-11-30 15297064 core:IntangibleAssetsOtherThanGoodwill 2024-12-01 2025-11-30 15297064 core:IntangibleAssetsOtherThanGoodwill 2025-11-30 15297064 core:IntangibleAssetsOtherThanGoodwill 2023-11-20 2024-11-30 15297064 core:IntangibleAssetsOtherThanGoodwill 2024-11-30

# TONIBOBANDLOU C.I.C.

## Company limited by guarantee

## Company Registration Number:
15297064 (England and Wales)

## Unaudited statutory accounts for the year ended 30 November 2025

## Period of accounts

## Start date: 1 December 2024

## End date: 30 November 2025

# TONIBOBANDLOU C.I.C.

## Contents of the Financial Statements

for the Period Ended 30 November 2025

Directors report |
Profit and loss |
Balance sheet |
Additional notes |
Balance sheet notes |
Community Interest Report |

# TONIBOBANDLOU C.I.C.

Directors' report period ended 30 November 2025

The directors present their report with the financial statements of the company for the period ended 30 November 2025

Principal activities of the company

TONIBOBANDLOU CIC is a UK Community Interest Company shaped by lived patient experience, specialising in evidence informed visual decision support for women needing a mastectomy, with or without breast reconstruction. Further information is included in the attached CIC 34 report.

Directors

The directors shown below have held office during the whole of the period from
1 December 2024 to 30 November 2025

Mrs Louise McKenna-Mayes
Mrs Antonia Ward

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
17 July 2026

And signed on behalf of the board by:
Name: Mrs Antonia Ward
Status: Director

# TONIBOBANDLOU C.I.C.

## Profit And Loss Account

for the Period Ended 30 November 2025

| 2025 | 2024
--- | --- | ---
| £ | £
Turnover: | 11,175 | 0
Cost of sales: | ( 2,826 ) | ( 464 )
Gross profit(or loss): | 8,349 | (464)
Administrative expenses: | ( 6,407 ) | ( 12,303 )
Other operating income: |  | 400
Operating profit(or loss): | 1,942 | (12,367)
Profit(or loss) before tax: | 1,942 | (12,367)
Profit(or loss) for the financial year: | 1,942 | (12,367)

# TONIBOBANDLOU C.I.C.

## Balance sheet

As at 30 November 2025

| Notes | 2025 | 2024
--- | --- | --- | ---
|  | £ | £
Fixed assets
Tangible assets: | 3 | 134 | 258
Total fixed assets: |  | 134 | 258
Current assets
Debtors: | 4 | 880 | 818
Cash at bank and in hand: |  | 7,018 | 5,013
Total current assets: |  | 7,898 | 5,831
Creditors: amounts falling due within one year: | 5 | ( 18,457 ) | ( 18,456 )
Net current assets (liabilities): |  | (10,559) | (12,625)
Total assets less current liabilities: |  | (10,425) | ( 12,367)
Total net assets (liabilities): |  | (10,425) | (12,367)
Members' funds
Profit and loss account: |  | (10,425) | ( 12,367)
Total members' funds: |  | ( 10,425) | (12,367)

The notes form part of these financial statements

# TONIBOBANDLOU C.I.C.

## Balance sheet statements

For the year ending 30 November 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 17 July 2026
and signed on behalf of the board by:

Name: Mrs Antonia Ward
Status: Director

The notes form part of these financial statements

# TONIBOBANDLOU C.I.C.

## Notes to the Financial Statements

for the Period Ended 30 November 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

  Turnover policy

  Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances. Sale of goods Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods. Rendering of services Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

  Tangible fixed assets depreciation policy

  Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases: Computer Equipment: Straight line basis over 3 years

  Other accounting policies

  Going Concern Disclosure: The directors confirm that, having considered their expectations and intentions for the next twelve months, and the availability of working capital, the company is a going concern. Taxation Income tax expense represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable surplus for the year. Taxable surplus differs from surplus as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable surplus. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable surplus will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable surplus will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. Current and deferred tax are recognised in surplus or deficit for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

# TONIBOBANDLOU C.I.C.

## Notes to the Financial Statements

for the Period Ended 30 November 2025

- ## 2. Employees

  | 2025 | 2024
  --- | --- | ---
  Average number of employees during the period | 0 | 0

# TONIBOBANDLOU C.I.C.

## Notes to the Financial Statements

for the Period Ended 30 November 2025

## 3. Tangible assets

| Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total
--- | --- | --- | --- | --- | --- | ---
Cost | £ | £ | £ | £ | £ | £
At 1 December 2024 |  |  |  | 372 |  | 372
Additions |  |  |  |  |  |
Disposals |  |  |  |  |  |
Revaluations |  |  |  |  |  |
Transfers |  |  |  |  |  |
At 30 November 2025 |  |  |  | 372 |  | 372
Depreciation |  |  |  |  |  |
At 1 December 2024 |  |  |  | 114 |  | 114
Charge for year |  |  |  | 124 |  | 124
On disposals |  |  |  |  |  |
Other adjustments |  |  |  |  |  |
At 30 November 2025 |  |  |  | 238 |  | 238
Net book value |  |  |  |  |  |
At 30 November 2025 |  |  |  | 134 |  | 134
At 30 November 2024 |  |  |  | 258 |  | 258

# TONIBOBANDLOU C.I.C.

## Notes to the Financial Statements

for the Period Ended 30 November 2025

## 4. Debtors

| 2025 | 2024
--- | --- | ---
| £ | £
Prepayments and accrued income | 815 | 818
Other debtors | 65 |
Total | 880 | 818

# TONIBOBANDLOU C.I.C.

## Notes to the Financial Statements

for the Period Ended 30 November 2025

## 5. Creditors: amounts falling due within one year note

| 2025 | 2024
--- | --- | ---
| £ | £
Trade creditors | 6,667 | 4,216
Accruals and deferred income | 1,790 | 4,240
Other creditors | 10,000 | 10,000
Total | 18,457 | 18,456

# COMMUNITY INTEREST ANNUAL REPORT

### TONIBOBANDLOU C.I.C.

### Company Number: 15297064 (England and Wales)

### Year Ending: 30 November 2025

Company activities and impact

During the 2024–2025 financial year, TONIBOBANDLOU CIC delivered a programme of work focused on improving the experience of women navigating mastectomy and breast reconstruction. The company produced, printed and introduced BRAVE v1.0, the UK’s first magazine style visual decision aid for mastectomy, designed and shaped with women of lived experience. BRAVE was adopted within Oxford University Hospitals, where Clinical Nurse Specialists and Consultants used it in pre-operative conversations to strengthen informed consent and reduce patient anxiety. As one clinician noted, “many finding the images reassuring and giving a better idea of what to expect.” The company completed a full qualitative evaluation involving 21 women, generating 916 analysable comments. Women described BRAVE as “calming, validating and empowering,” highlighting its role in improving understanding and confidence at a critical point in their cancer pathway. TONIBOBANDLOU CIC also expanded its representative image library through ongoing photography with women across multiple surgical stages, ensuring that BRAVE reflects real bodies and real timelines. More than 200 hours were invested in direct community engagement, including interviews, photography sessions, return visits and individual image presentations. This relational approach ensured that BRAVE was shaped with women, not simply informed by them. Beyond direct patient impact, the company contributed to national sector learning. BRAVE was shared with over 150 professionals through webinars, NHS England meetings, Cancer Alliance discussions and national events. The organisation strengthened partnerships with Against Breast Cancer, Thames Valley Cancer Alliance and other charities, supporting recruitment, visibility and alignment with NHS priorities. The company also held a community fundraising event, presented BRAVE publicly for the first time, and continued to build a supportive network of women, clinicians and advocates. Together, these activities delivered clear community benefit by improving access to realistic imagery, contextualised information and emotionally intelligent decision support for women facing complex surgical decisions.

Consultation with stakeholders

TONIBOBANDLOU CIC engages a wide range of stakeholders who are directly affected by, or contribute to, the development and use of BRAVE. These include women with lived experience of mastectomy and breast reconstruction, Clinical Nurse Specialists, Consultants, surgical advisors, national breast cancer charities, Cancer Alliances, researchers, and wider professional networks across the UK. Women of lived experience: Women were central to all decision-making and design processes. Across the year, the company invested over 200 hours in interviews, photography sessions, return visits, image review conversations and individual presentations of their photographs. Women provided detailed feedback through a full qualitative evaluation (21 participants, 916 analysable comments). Their reflections shaped the emotional tone, clarity of information, diversity of imagery and accessibility of BRAVE v1.0. Women described BRAVE as “calming, validating and empowering,” and their feedback directly informed refinements for BRAVE v1.1 and future versions. Clinical stakeholders: Clinical Nurse Specialists and Consultants at Oxford University Hospitals used BRAVE v1.0 in pre-operative conversations and provided ongoing feedback on its clinical utility. As one Specialist Nurse noted, “many finding the images reassuring and giving a better idea of what to expect.” Their insights guided improvements to sequencing, clarity of surgical explanations and the integration of BRAVE into informed consent discussions. BRAVE was also used within NHS training by Assistant Professor Dr Gemma McKenna, whose feedback strengthened the resource’s alignment with shared decision making principles. Charities and sector organisations: Stakeholders such as Against Breast Cancer, Thames Valley Cancer Alliance, Breast Cancer Now and Future Dreams House provided feedback on recruitment, sector needs and patient information gaps. Their input supported alignment with NHS priorities, strengthened visibility, and informed strategic planning for wider adoption. Professional networks and national engagement: Over 150 professionals engaged with BRAVE through webinars, NHS England meetings, sector events and national conferences. Feedback emphasised the importance of realistic imagery, lived experience insight and emotionally intelligent information. This consultation reinforced BRAVE’s relevance and guided the development of future versions and partnership pathways. Community stakeholders: A community fundraising event provided an opportunity for supporters and partners to engage with BRAVE directly. Feedback from this event informed how the resource is presented publicly and helped shape communication materials for wider audiences. Actions taken in response to stakeholder feedback: Stakeholder consultation directly influenced the refinement of BRAVE v1.0, the design of BRAVE v1.1, the expansion of the image library, improvements to clinical clarity, and the strategic direction for NHS Cancer Alliance adoption. Feedback also shaped the emotional tone, accessibility and representativeness of the resource, ensuring it remains grounded in lived experience and clinical need.

Directors' remuneration

The Co-Founders of the CIC, bill monthly a symbolic remuneration of £0.17. This figure represents the 1 in 7 women who are diagnosed with Breast Cancer in the UK every year.

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
8 July 2026

And signed on behalf of the board by:
Name: Louise Mckenna-Mayes
Status: Director